Br Med J (Clin Res Ed). 1988 Feb 13;296(6620):468-72.
A randomised double blind parallel group study was performed to compare the efficacy and acceptability of slow release nifedipine (maximum dose 40 mg twice a day) with those of atenolol (maximum dose 100 mg once a day) as single agents for the treatment of essential hypertension. Of 410 patients recruited almost exclusively from general practices in 22 centres in the United Kingdom 210 received nifedipine and 200 atenolol. Both drugs significantly reduced blood pressure, and control--a reduction of the diastolic pressure to less than 95 mm Hg--was obtained in about 65% of patients. Those who received nifedipine had more pronounced reductions in systolic pressure than those who received atenolol. One hundred and forty nine patients who failed to respond adequately to either atenolol or nifedipine in low doses were given both drugs once daily for eight weeks in a fixed combination capsule that contained atenolol 50 mg and nifedipine 20 mg. All patients showed further reductions in blood pressure, although those who were taking beta atenolol before the combination capsule had more pronounced reductions in systolic pressures. Twenty six patients (12%) were withdrawn because of adverse effects while taking nifedipine compared with 19 (10%) taking atenolol. Flushing and oedema were more common after the calcium antagonist, whereas diarrhoea and dyspepsia were more common after atenolol. The frequencies of headaches, dizziness, fatigue, and dyspnoea were equally distributed between the two groups. When the fixed combination capsule was taken side effects such as flushing and oedema continued. Nifedipine was more effective than atenolol in lowering systolic blood pressure, although neither drug used alone controlled the pressure of more than two thirds of the patients studied. When used in a fixed combination slightly better control of blood pressure was achieved with a lower dose of each drug.
进行了一项随机双盲平行组研究,以比较缓释硝苯地平(最大剂量为每日两次,每次40毫克)与阿替洛尔(最大剂量为每日一次,每次100毫克)作为单一药物治疗原发性高血压的疗效和可接受性。在英国22个中心几乎全部从普通诊所招募的410名患者中,210名接受硝苯地平治疗,200名接受阿替洛尔治疗。两种药物均能显著降低血压,约65%的患者血压得到控制,即舒张压降至95毫米汞柱以下。接受硝苯地平治疗的患者收缩压下降比接受阿替洛尔治疗的患者更显著。149名对低剂量阿替洛尔或硝苯地平反应不佳的患者,服用一种固定复方胶囊,其中含有50毫克阿替洛尔和20毫克硝苯地平,每日一次,持续八周。所有患者血压进一步下降,尽管在服用复方胶囊前服用β受体阻滞剂阿替洛尔的患者收缩压下降更显著。服用硝苯地平时有26名患者(12%)因不良反应退出研究,而服用阿替洛尔的有19名患者(10%)。服用钙拮抗剂后潮红和水肿更常见,而服用阿替洛尔后腹泻和消化不良更常见。头痛、头晕、疲劳和呼吸困难的发生率在两组中分布相同。服用固定复方胶囊时,潮红和水肿等副作用仍会出现。硝苯地平在降低收缩压方面比阿替洛尔更有效,尽管单独使用这两种药物时,控制的患者均未超过研究患者的三分之二。当两种药物以固定复方使用时,使用较低剂量可实现稍好的血压控制。